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Abstract
Background: Angiogenesis is a key process in several ocular disorders and cancers. Soluble Flt-1 is an alternatively spliced
form of the Flt-1 gene that retains the ligand-binding domain, but lacks the membrane-spanning and intracellular kinase
domains of the full-length membrane bound Flt-1 (mbFlt-1) protein. Thus, sFlt-1 is an endogenous inhibitor of VEGF-A
mediated angiogenesis. Synthetic mopholino oligomers directed against splice site targets can modulate splice variant
expression. We hypothesize that morpholino-induced upregulation of sFlt-1 will suppress angiogenesis in clinically relevant
models of macular degeneration and breast cancer.
Methods and Findings: In vivo morpholino constructs were designed to target murine exon/intron 13 junction of the Flt-1
transcript denoted VEGFR1_MOe13; standard nonspecific morpholino was used as control. After nucleofection of
endothelial and breast adenocarcinoma cell lines, total RNA was extracted and real-time RT-PCR performed for sFlt-1 and
mbFlt-1. Intravitreal injections of VEGFR1_MOe13 or control were done in a model of laser-induced choroidal
neovascularization and intratumoral injections were performed in MBA-MD-231 xenografts in nude mice. VEGFR1_MOe13
elevated sFlt-1 mRNA expression and suppressed mbFlt-1 mRNA expression in vitro in multiple cellular backgrounds
(p,0.001). VEGFR1_MOe13 also elevated sFlt/mbFlt-1 ratio in vivo after laser choroidal injury 5.5 fold (p,0.001) and
suppressed laser-induced CNV by 50% (p=0.0179). This latter effect was reversed by RNAi of sFlt-1, confirming specificity of
morpholino activity through up-regulation of sFlt-1. In the xenograft model, VEGFR1_MOe13 regressed tumor volume by
88.9%, increased sFlt-1 mRNA expression, and reduced vascular density by 50% relative to control morpholino treatment
(p,0.05).
Conclusions: Morpholino oligomers targeting the VEGFR1 mRNA exon/intron 13 junction promote production of soluble
FLT-1 over membrane bound FLT-1, resulting in suppression of lesional volume in laser induced CNV and breast
adenocarcinoma. Thus, morpholino manipulation of alternative splicing offers translational potential for therapy of
angiogenic disorders.
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Introduction
Angiogenesis, though a fundamental physiologic process, is a
key pathogenetic feature of numerous disease states. At present,
therapeutic strategies have limited potential largely due to the fact
that the underlying mechanisms of angiogenesis are incompletely
understood. Work to elucidate the full complement of mediators
and mechanisms important for angiogeneis, and further apply this
knowledge in such a way to alter disease progression continues to
be the foremost goal within the field.
Identification of VEGF as a critical mediator of vessel growth
has been an important step to understanding the human condition
in terms of the underlying molecular events. VEGF has been
shown to be necessary and sufficient for ocular neovascularization
[1–4]. In fact, transgenic mice which over-express human VEGF
show widespread ocular neovascularization [5–6]. Additionally,
pioneering work by Judah Folkman in the early 1970’s demons-
trated that solid tumor growth required VEGF expression [7].
However, it is not fully known what specific molecular media-
tors regulate VEGF expression. Soluble Flt-1, first described by
Kendall and Thomas in 1993, is an alternatively spliced form of
the Flt-1 gene, also referred to as VEGF-receptor 1 [8]. This
alternative splicing event occurs within intron 13 such that sFlt-1
contains the ligand-binding domain, but lacks the membrane-
spanning and intracellular kinase domains of the full-length mem-
brane bound Flt-1 (mbFlt-1) protein [9]. As suggested by its
structure, sFlt-1 is a potent endogenous inhibitor of VEGF A-
induced angiogenesis [9]. While the full complement of sFlt-1
expression and function has not been described, it has been shown
to be both necessary and sufficient for maintenance of the
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a role for modulation of sFlt-1 in the development and treatment
of a form of pathologic ocular neovascularization termed choroidal
neovasculization (CNV), via modulation of VEGF ([11–12],
unpublished data). Choroidal neovascularization is characterized
by choroidal capillary growth through Bruch’s membrane beneath
the retinal pigmented epithelial (RPE) cell layer. This vascular
pathology is most classically seen in exudative or ‘‘wet’’ age-related
macular degeneration, the leading cause of vision loss in the
western world [13–14]. Furthermore, sFLT-1 has also been shown
to reduce VEGF expression and tumor vascularity in breast
adenocarcinoma xenografts [15]. Thus, sFlt-1 represents a
potential therapeutic target to reduce aberrant blood vessel growth
over a spectrum of disease.
Current therapies targeting both CNV and tumor vasculature
are focused on inhibiting the new vessel growth, and include such
modalities as photocoagulation, photodynamic therapy, anti-
VEGF intraocular injections, as well as systemic administration
of anti-VEGF monoclonal antibody. These approaches have
shown promise; however, they induce retinal damage, require
repeated intraocular administration, or have recently been
contraindicated for use in the case of systemic anti-VEGF therapy
for breast adencarcinoma [4,13,16–17]. Additionally though
certainly progress has been made, incomplete efficacy and
recurrence is commonly seen with all modalities. Development
of novel therapeutic techniques to either augment or circumvent
our current treatments is necessary to improve both efficacy and
the risk profile.
In this work, we describe the use of morpholino oligomers
promoting the expression of soluble Flt-1 as a means to determine
its potential for therapeutic use in disorders characterized by
aberrant neovascularization. This technology has human prece-
dent in Duchene Muscular Dystrophy, where morpholino
technology targeting the dystrophin gene has shown efficacy in
splice site alteration and disease modification in both animal and
human trials [18–20]. Our work demonstrates the use of
morpholino oligomers alters the splicing of VEGFR1 such that
production of soluble Flt-1 is favored both in vitro and in vivo.
Furthermore, we demonstrate the efficacy of increased sFlt-1
expression in treatment of aberrant blood vessel growth in ocular
and cancer disease models. Thus, morpholino technology holds
promise for use in the context of human disease.
Results
VEGFR1_MOe13 promotes a shift from membrane
VEGFR1 to soluble VEGFR1 in vitro
In order to demonstrate the utility of morpholino constructs for
modulating sFLT-1 expression, morpholino oligomers were de-
signed targeting the FLT-1 mRNA exon13-intron13 junction
(VEGFR1_MOe13) or intron13_exon14 junction (VEGFR1_
MOi13). The canonical Flt-1 gene consists of thirty exons in human
and mouse. Full-length mRNA from all exons produces mbFLT-1.
By contrast, sFLT-1 utilizes a polyadenylation site within intron13.
Therefore, interaction between the morpholino constructs and
VegfR1 pre-mRNA is predicted to influence the alternative splicing
event such that production of soluble FLT-1 is favored. To directly
measure the relationship between membrane bound and soluble
FLT-1 in the presence of VEGFR1_MOe13 and VEGFR1_
MOi13, human umbilical vein endothelial cells (HUVEC) were
electroporated with targeting or standard morpholino oligomers
designed against human VEGFR1. Using this technique MO
constructs were found to sufficiently access the nuclear compart-
ment (Fig. 1a). Forty-eight hours after electroporation, total RNA
was harvested and soluble VEGFR1 and membrane VEGFR1
mRNAexpressionwasassessed usingreal-timePCR.Wefoundthat
VEGFR1_MOe13, VEGFR1_MOi13, and a combination of
a combination of one-half dose of both VEGFR1_MOe13 and
VEGFR1_MOi13 significantly decreased membrane VEGFR1
mRNA and increased soluble VEGFR1 mRNA (Fig. 1b–c;
Figure S1). To determine if the VEGFR1 morpholino constructs
also affected soluble FLT-1 expression at the protein level, soluble
VEGFR1 protein in HUVEC culture medium was measured by
ELISA in the presence or absence of the VEGFR1 morpholino
constructs or control mopholino. VEGFR1_MOe13 increased
soluble VEGFR1 protein production as compared with standard
morpholino or control PBS conditions (Fig. 1d). In contrast,
VEGFR1_MOi13 were less effective, whereas combined delivery of
both VEGFR1_MOi13 and VEGFR1_MOe13 showed interme-
diate response, possibly due to competitive interference or reduced
efficacy of one morpholino as compared with the other. Thus,
morpholino targeting of the FLT-1 mRNA exon13-intron13
junction using VEGFR1_MOe13 is most efficacious for increasing
sFLT-1 and decreasing mbFLT-1 expression in vitro.
To ensure that this effect was not cell line specific, we sought to
validate our findings in other cellular backgrounds. Although
soluble FLT-1 is predominantly a product of endothelial cells per
its role in angiogenesis, it is also expressed by a number of other
cell types including tumor cells [15,21–24]. Thus, we sought to
determine whether expression of the VEGFR1_MOe13 in MCF7
and MBA-MD-231 breast adenocarcinoma cells would increase
soluble FLT-1 levels. As demonstrated in figure 2, electroporation
of VEGFR1_MOe13 directed against the human FLT-1 tran-
script increases soluble FLT-1 RNA and decreases membrane
FLT-1 RNA in both adenocarcinoma lines (Fig. 2a–d).
VEGFR1_MOe13 increases sFlt/mFlt mRNA ratio in the
mouse retina and suppresses laser-induced choroidal
neovascularization volume in vivo
In order to directly test the efficacy of the VEGFR1_MOe13 for
both in vivo activity as well as predicted effect on the process of
angiogenesis we adopted the well established murine model of
laser-induced choroidal neovascularization which induces signifi-
cant CNV lesions 1 week after laser injury [25–26]. We
hypothesized that expression of VEGFR1_MOe13 in vivo would
both increase soluble Flt-1 levels and lead to suppression of laser-
induced CNV. To first evaluate the effectiveness of VEGFR1_
MOe13 to modulate sFlt-1 levels in vivo, we examined the sFlt/
mFlt mRNA ratio in the mouse retina 24 hours after injection with
PBS, vivo-standard_MO, or vivo-VEGFR1_MOe13 designed to
target murine sFlt-1 (the ‘‘vivo’’ denotes modification allowing
MO construct to enter cells in vivo as demonstrated [27]). We
found that intra-vitreol injection of vivo-VEGFR1_MOe13 leads
to a significant increase of sFlt/mFlt mRNA ratio as compared
with PBS or vivo-standard_MO injection (Fig. 3a). Thus,
VEGFR1_MOe13 expression is sufficient to increase soluble Flt-
1 expression in vivo.
To determine whether VEGFR1_MOe13 expression in vivo
could suppress development of CNV in the setting of laser insult,
vivo-VEGFR1_MOe13, vivo-standard_MO or PBS were injected
intra-vitreously on day 1 and day 4 after laser photocoagulation.
One week after laser photocoagulation, eyes were enucleated and
the degree of CNV volume was measured by confocal microscope
after isolectin GS-IB4 vasculature staining. CNV volumes were
quantified using confocal microscopy. Murine eyes treated with
intra-vitreal vivo-VEGFR1_MOe13 displayed a statistically sig-
nificant decrease in CNV volume as compared with eyes treated
with either vivo-standard morpholino or PBS controls (Fig. 3b–d).
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increased levels of sFlt-1 and suppression of laser-induced CNV.
Short hairpin RNA-mediated sFlt-1 knock-down ‘‘rescues’’
the CNV phenotype in vivo
In order to demonstrate that the measured effect of reduced CNV
following intra-vitreol injection of VEGFR1_MOe13 was specific for
an increase in sFlt-1 expression, we knocked-down sFlt-1 expression
AAV2_shsFlt encoding short hairpin RNA(shRNA) targeting sFlt-1
mRNA (unpublished data; [10]). Intra-vitreol injections were
performed using PBS, AAV2_shNEG (non specific shRNA) or
AAV2_shsFlt (shRNA targeting sFlt-1) and laser photocoagulation
p e r f o r m e d2w e e k sl a t e r .I nac o n s i s t e n tf a s h i o nw i t hp r i o rs t u d i e s ,o n
day 1 and 4 following photocoagulation PBS, vivo-standard_MO or
vivo-VEGFR1_MOe13 constructs were injected into pretreated eyes.
We hypothesized that if increased sFlt-1 was sufficient for suppression
of the laser-induced CNV phenotype, co-expression of AAV2_shR-
NA_sFlt would reverse this effect. In agreement with this hypothesis,
we observed that pre-treatment with AAV2_shsFlt results in reversal
of VEGFR1_MOe13-mediated CNV suppression (Fig. 4). Thus,
increased soluble Flt-1 expression is sufficient to at least partially
mediate CNV suppression in the setting of laser-induced injury.
Figure 1. VEGFR1_MOe13 localizes to the nucleus and increases sFLT-1 expression in human endothelial vein cells (HUVEC). (a)
Fluorescently tagged VEGFR1_MOe13 (F-MO) or standard morpholino (std-MO) were electroporated into HUVECs. After 48 hours fluorescence was
assessed using light microscopy. Colocalization with DAPI staining represents nuclear localization of morpholino constructs. HUVECs were
electroporated with VEGFR1_MOe13, VEGFR1_MOi13, a combination of VEGFR1_MOe13 and VEGFR1_MOi13, Standard_MO. All morpholino
sequences were designed to target the human VEGFR1 transcript. (b) mbFLT-1 mRNA (n=6) or (c) sFLT-1 mRNA expression (n=6) were assessed
using real time PCR. Values were normalized to GAPDH mRNA and normal HUVEC was used as 1.0. (d) sFLT protein expression in culture medium was
determined by ELISA (n=3). Data shows sFLT protein at 96 h – 48 h. Error bar is S.E.M. Each p-value was calculated by two-tail student’s t-test against
normal HUVEC.
doi:10.1371/journal.pone.0033576.g001
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adenocarcinoma xenograft tumors with VEGFR1_MOe13
results in tumor regression
In order to demonstrate that anti-angiogenic activity of the
VEGFR1_MOe13 construct is not limited to the ocular compart-
ment, we sought to measure its efficacy in the setting of malignancy-
associated neovascularization. Tumor vasculature is a rapidly
emerging therapeutic target. As such, this model represents an
attractive context in which to apply technologies designed to inhibit
neovascularization. Within the context of malignancy, breast
adenocarcinoma is known to demonstrate marked dependence on
VEGF signaling for sustained neovascularization and growth [28–
29]. In fact, VEGF inhibition has been shown to reduce tumor
growth in both the experimental as well as the clinical setting
[17,30]. We hypothesized that treatment of MBA-MD-231 human
breast adenocarcinoma xenograft tumors with vivo-VEGFR1_
MOe13 would result in increased levels of soluble Flt-1 and a
subsequent decrease in neovascularization and tumor regression.
To directly test this hypothesis, femalenude mice were inoculated as
described. Xenografts were permitted to grow for 14 days. Tumors
were then directly injected with either murine vivo-VEGFR1_
MOe13 or vivo-standard morpholino. Injections and tumor volume
assessments wereperformedbi-weeklyfora duration of4 weeks.We
found that treatment of xenograft tumors with vivo-VEGFR1_
MOe13 led to tumor regression when compared with standard
morpholino treatment (p=0.04) (Fig. 5a). Furthermore, murine
sFlt-1 mRNA transcript levels were increased and mbFlt-1 mRNA
levels decreased in treatment tumors at the conclusion of the 4 week
treatment period as compared with control tumors when assessed
using real-time PCR (Fig. 5b–c). Finally, to determine whether
vascular density was decreased in tumors treated with viv-
VEGFR1_MOe13 injection, tumor vasculature was stained with
GS-IB4 and vessel density quantified using fluorescence microscopy
following the 4 week treatment period. Tumors treated with the
vivo-VEGFR1_MOe13 construct demonstrated a statistically sig-
nificant decrease in vascular density (Fig. 5d). Interestingly, these
results were achieved using VEGFR1_MOe13 targeting the murine
Flt-1transcript,whiletreatment withaVEGFR1_MOe13construct
targeting human FLT-1 did not demonstrate tumor regression in
vivo (Figure S2). Thismay indicate that host vasculature is important
for tumor growth,, suggesting that human sFLT-1 produced by
tumor cells does not effectively inhibit murine VEGF signaling.
However, analysis of the human and murine morpholino sequences
demonstrates significant overlap between the murine morpholino
construct with the human VEGFR1 sequence. The same is not true
for the human morpholino with respect to the murine VEGFR1
mRNA sequence. Therefore, this cross-reactivity could account for
our findings as could overall decreased efficacy of the human
morpholino construct. The latteris unclear given the fact that in vitro
this sequence increases soluble FLT-1 very effectively. Further
studies are needed to fully understand this.
Figure 2. VEGFR1_MOe13 increases sFLT-1 and decreases mbFLT-1 mRNA in MCF-7 and MBA-MD-231 breast adenocarcinoma cell
lines. MCF7 or MBA-MD-231 human breast adenocarcinoma cells were electroporated with VEGFR1_MOe13 and (a; c) sFLT-1 and (b; d) mbFLT-1
mRNA levels assessed at 72 hours using real time PCR (n=3). Data were normalized to GAPDH mRNA levels and normal MCF7 or MBA-MD-231 cells
were used a 1.0. *p,0.01.
doi:10.1371/journal.pone.0033576.g002
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Neovascularization is a common pathological process under-
pinning numerous disease states. Elucidation of key molecular
mediators has allowed for the development of therapeutic
strategies targeting the underlying molecular processes. Soluble
Flt-1 first described in 1993, is an alternatively spliced form of the
Flt-1 gene [4–5]. The morpholino oligomer VEGFR1_MOe13 is
designed to target the Flt-1 mRNA exon13-intron13; therefore,
interaction between VEGFR1_MOe13 and VegfR1 pre-mRNA is
predicted to influence the alternative splicing event such that
production of soluble Flt-1 is promoted.
Herein we demonstrate that expression of VEGFR1_MOe13
both in vitro and in vivo results in elevated levels of soluble Flt-1 and
decreased membrane bound Flt-1. Furthermore, these data show
that VEGFR1_MOe13-mediated increase in soluble Flt-1 within
the retina can prevent choroidal neovascularization following laser
photocoagulation. Finally, our data indicate that this phenotype is
attributable to increased sFlt-1 expression as co-treatment with
sFlt-1-RNAi negates this effect. Thus, soluble Flt-1 expression is
both necessary and sufficient for suppression of laser-induced
CNV. Taken together these data indicate that modulation of
soluble Flt-1 expression in the clinical setting has potential
therapeutic value. This represents great promise when considering
the over 7 million patients in the US alone with non-exudative age
related macular degeneration (ARMD) currently ‘‘at risk’’ for
development of CNV.
Angiogenesis in the form of aberrant neovascularization is
fundamental to the pathophysiology of other disease states as well.
Notably, new blood vessel formation is absolutely required for
sustained solid tumor growth [7]. As noted, breast adenocarcino-
ma is dependent on sustained neovascularization both in animal
and human studies [28–29]. As a ‘‘proof of principle’’ for broad
Figure 3. VEGFR1_MOe13 inhibits laser-induced CNV in vivo. a. sFlt/mFlt mRNA ratio in the retina treated with PBS, Standard_MO and
VEGFR1_MOe13 (n=4). Representative images of laser CNV injected with b PBS, c Standard_MO and d VEGFR1_MOe13 designed to target the murine
VEGFR1 transcript. e The averages of laser CNV volumes (n=11–14). Error bar is S.E.M. p-values were calculated by two-tail student’s t test.
doi:10.1371/journal.pone.0033576.g003
Figure 4. RNAi targeting sFlt-1 rescues the neovascular
phenotype response to laser injury. Murine eyes were treated
with PBS, AAV2_shNEG or AAV2_shsFLT. After 2 weeks, laser photo-
coagulation was performed. On 1 day and 4 day after photocoagula-
tion, PBS Standard_MO or VEGFR1_MOe13 were injected. Error bar is
S.E.M. N=9–15.
doi:10.1371/journal.pone.0033576.g004
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treatment of neovascular disease, we demonstrate that intra-
tumoral injection of VEGFR1_MOe13 leads to increased intra-
tumoral levels of sFlt-1 and decreased mbFlt-1.. Furthermore,
breast adenocarcinoma xenografts expressing elevated levels of
sFlt-1 demonstrate a blunted neovascular response and regress
once established as compared with control tumors. Thus,
modulation of soluble Flt-1 expression using morpholino technol-
ogy represents a therapeutic tool with broad applicability across a
spectrum of neovascular disease.
Taken together, these data indicate that morpholino expression
is a viable tool for modulating the expression of FLT-1, i.e., the
balance between membrane and soluble forms of this transcript. In
our system, these data indicate that morpholino interference at the
Flt-1 mRNA exon13-intron13 junction leads to the greatest
amount of soluble FLT1 production. The VEGFR1_MOe13
construct is effective in two independent disease models, choroidal
neovascularization and breast adenocarcinoma. In both, aberrant
vasculature and disease burden are reduced. Given the highly
divergent roles of FLT1 isoforms, morpholino oligos show promise
in a variety of physiologic settings and disease states to act as an
‘‘exogenous switch’’ to modulate angiogenesis.
These data demonstrate the efficacy of morpholino technology to
influenceFLT-1gene expression atthe mRNAlevel bothin vitroand
in vivo setting. Recent application of splice-blocking morpholinos in
the setting of DMD has demonstrated disease-modifying effects in
both animal and human trials [18–20]. Therefore, these constructs
hold promise as true ‘‘bench to bedside’’ tools. Within the setting
of neovascularization, use of morpholino technology represents
a shift from current therapies which are predominantly based
on monoclonal antibody approaches. The evolving potential for
morpholino technology to be targeted to areas of pathology
following systemic administration may lend this technology to
broader appeal and utility [31]. Additionally, combining morpho-
lino-mediated sFLT-1 modulation with other known anti-angio-
genic strategies is a promising area of investigation. For example,
Figure 5. Intra-tumoral VEGFR1_MOe13 injection results in regression of established MBA-MD-231 human breast adenocarcinoma
xenograft tumors and decreased tumor vascularity. a. MB-MDA-231 breast cancer cells were grown as xenografts in female nude mice for 2
weeks prior to beginning treatment with either a standard morpholino or VEGFR1_MOe13 designed to target the murine VEGFR1 transcript.
Morpholino treated tumors demonstrate size regression after a 4 week treatment course as demonstrated by volume change analysis of 5 individual
tumors within each treatment condition. p=0.04 b–c. Following treatment course, RNA was extracted from xenograft tumors and soluble or
membrane bound Flt1 levels were measured using real-time RT-PCR. Error bars indicate variation between individual PCR reactions per tumor sample.
d. Following the treatment course, VEGFR1_MOe13 or standard morpholino xenograft tumors were sectioned and stained with isolectin as a measure
of vascularity. Individual bars represent sections analyzed thoughout each tumor sample.
doi:10.1371/journal.pone.0033576.g005
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FGF and PDGF remains an interesting question, as these factors
have been shown to promote intra-ocular neovascularization and
inhibition shown to reduce neovascular pathology [32–34].
Furthermore, synergy between these pathways has been shown to
promote tumor vascularity and metastasis in murine studies [35–
36]. Therefore, steric inhibition of splice sites required for proper
expression of these factors may represent yet another role for
morpholino technology in the treatment of neovascular disease.
Thus morpholino technology currently represents an effective
mechanism for treatment of neovascular pathology across a
spectrum of disease with high translational potential and exciting
future applications.
Materials and Methods
Constructs and Reagents
In vivo morpholino constructs were designed to target murine
intron/exon 13 junction of the FLT-1 transcript denoted
VEGFR1_MOe13 and VEGFR1_MOi13. Constructs were
chemically modified such that they would easily diffuse to access
the intracellular compartment [27]. For use in xenograft assays,
VEGFR1_MOe13 morpholino constructs were suspended in
sterile PBS and used at a concentration of 400 ng/dose. Each
dose is equal to 50 ul total volume. A standard morpholino
targeting the murine beta-globin subunit2 was used as a control
and prepared at the same concentration. Morpholino sequences
are as follows.
Human VEGFR1_MOe13 GTTGCAGTGCTCACCTCT-
GATTGTA
Human i13 GCTTCCTGATCTAGTGAAGAAAGAA
Mouse VEGFR1_MOe13 CTTTTTGCCGCAGTGCTCAC-
CTCTA
STD MO CCTCTTACCTCAGTTACAATTTATA
AAV.shRNA.sFlt-1 was developed as previously described [11].
2.5610‘9 GC of AAV.shRNA.sFlt-1 were injected per experi-
mental condition.
Cell culture
Primary human umbilical vein endothelial cells (Lonza,
Walkersville, MD, USA) were cultured in EBM with EGM
SingleQuot Kit supplements and growth factors according to
the manufacturer’s instructions (Lonza, Walkersville, MD, USA).
To prevent loss of endothelial cell properties, cell cultures were
limited to passage number 4 to 7. MBA-MD-231 human breast
adenocarcinoma cells were obtained from the laboratory of Dr.
Bryan Welm MD at the Huntsman Cancer Institute, SLC, Utah
and maintained in RPMI culture medium containing 10% FBS.
MCF7 human breast adenocarcinoma cells were obtained for the
laboratory of Dr. Alana Welm PhD at the Huntsman Cancer
Institute, SLC, Utah and maintained per ATCC medium
recommendations.
Morpholino delivery to cultured cells and total RNA
extraction
10 ng of morpholinos were delivered to the nucleus by
nucleofection (Amaxa, Gaithersburg, MD, USA) using a Basic
Nucleofector Kit for Primary Mammalian Endothelial Cells
(Amaxa, Gaithersburg, MD, USA), program A-034 for HUVEC.
For one nucleofection, 16106 cells were used and plated on a 6-
well plate. After 2 days of culture, cells were trypsinized and total
RNA was extracted using a RNeasy mini kit (Qiagen, Valencia,
CA, USA)]. RNA concentrations were determined by 260 nm
absorption measured with a spectrophotometer.
Complementary DNA synthesis and quantification with
real-time PCR
Complementary DNA (cDNA) were synthesized from approx-
imately 400 ng total RNA using an Omniscript RT kit (Qiagen,
Valencia, CA, USA) and Oligo-dT primer (dT2) according to the
manufacturer’s instructions. Real-time PCR was performed using
a QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA,
USA) and an aliquot 1:l of cDNA solution. The primer sequences
used for human sequence real-time PCR were:
VEGFR1_F1: 59-CTGCAAGATTCAGGCACCTA-39
VEGFR1_R1: 59- CCTTTTTGTTGCAGTGCTCA-39
VEGFR1_F2: 59-AACCAGAAGGGCTCTGTGGAAAGT-39
VEGFR1_R2: 59-CAAACTCCCACTTGCTGGCATCAT-39
The combination of VEGFR1_F1 and R1 was designed to
detect the soluble form of human VEGFR1. The combination of
VEGFR1_F2 and R2 was designed to detect the membrane form
of human VEGFR1 .
The primer sequences used for murine sequence real-time PCR
were:
VEGFR1_F1: 59 –AATGGCCACCACTCAAGATT
VEGFR1_R1: 59 –TTGGAGATCCGAGAGAAAATG
VEGFR1 F2: 59 –GATCAAGTTCCCCTGGATGA
VEGFR1_R2: 59 –ATGCAGAGGCTTGAACGACT
Gapdh_F: 59 –AACTTTGGCATTGTGGAAGGGCTC
Gapdh_R: 59 -ACCAGTGGATGCAGGGATGATGTT
The combination of VEGFR1_F1 and R1 was designed to
detect the soluble form of murine VEGFR1. The combination of
VEGFR1_F2 and R2 was designed to detect the membrane form
of murine VEGFR1 .
Real-time PCR conditions: 50uC for 2 minutes, 95uC for
10 minutes, followed by 40 cycles of 94uC for 15 seconds, 55uC
for 30 seconds, and 72uC for 30 seconds.
Laser induced choroidal neovascularization
Laser photocoagulation (532 nm, 150 mV, 100 ms, 100 mm;
NIDEK MC-4000) was performed on both eyes (2 to 5 spots per
eye) as described [24–25]. After enucleating the eyes, sclera/
choroid/RPE complex were fixed in 4% paraformaldehyde for
2 hours at 4uC. After blocking in 5% FBS/PBS with 0.02%
tritonX-100 and 2 mM MgCl2, samples were stained with 5 mg/
ml Alexa488 and Alexa546 conjugated isolectin GS-IB4 (Invitro-
gen Corporation, Carlsbad, USA) overnight. After washing the
samples were flat mounted on glass slides. CNV volume was
measured by scanning laser confocal microscopy (Olympus
America Inc., Center Valley, USA). These animal studies were
performed under IACUC protocol approval number 09-03005
approved by the Committee on the Ethics of Animal Experiments
at the University of Utah. All interventions were performed either
under sodium pentobarbital anesthesia or after animals were
humanely euthanized.
Xenograft analysis
3610
6 MBA-MD-231 human breast adenocarcinoma cells were
injected subcutaneously into the flanks of female nude mice.
Following a standardized 2 week inoculation period, xenograft
tumors were injected biweekly for a total duration of 4 weeks
with VEGFR1_MOe13 or standard morpholino control. These
constructs were prepared as detailed above. Tumor growth was
assessed using digital calipers with bi-weekly measurements
correlating with injection period. (Volume mm
3=width
26
length/2. These animal studies were performed under IACUC
protocol approval number 09-03005 approved by the Committee
on the Ethics of Animal Experiments at the University of Utah. All
sFLT-1 Moropholino Decreases Neovascularization
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anesthesia or after animals were humanely euthanized.
Immunohistochemical anlaysis
Tumors were fixed in 4% paraformaldehyde for 2 h at 4 C,
cryoprotected in 15% sucrose and 30% sucrose, and then
embedded in OCT (Tissue-Tek, USA). Sections (12 um) were
cut and were incubated with isolectin (Griffonia simplicifolia,
Alexa Fluo568 conjugate 1:1000, Invitrogen Corporation, Carls-
bad, CA) overnight. Immunohistochemistry results were examined
using scanning laser confocal microscopy (Olympus, FLUO-
VIEW, FV1000, 206). These images were scored by Image-J
morphometry system using biometry scoring (Wayne Rasband).
After electroporation of F-MO(10 ul of 1 mM) or STD MO
into HUVECs, the cells were plated to 8 well glass slide (nunc,
Rochester, NY) coated with collagen. 24 hours later, the cells were
fixed with 4% parafolmaldehyde/PBS, stained with DAPI, and
observed with the Zeiss Axiovert 200 inverted fluorescence
microscope.
Statistical analysis
Data are presented as mean +/2SEM. Statistical analysis was
performed using student T test. A p-value 0.05 was considered
significant.
Supporting Information
Figure S1 The Soluble/Membrane FLT-1 ratio increases
following electroporation of VEGFR1_MOe13 into HUVEC.
HUVECs were electroporated with VEGFR1_MOe13, VEGFR1_
MOi13, a combination of VEGFR1_MOe13 and VEGFR1_
MOi13, Standard_MO. All morpholino sequences were designed
to target the human VEGFR1 transcript. mbFLT-1 mRNA and
sFLT-1 mRNA expression were assessed using real time PCR.
Values were normalized to GAPDH mRNA and normal HUVEC
was used as 1.0.
(TIF)
Figure S2 Intra-tumoral injection of VEGFR1_MOe13 target-
ing human FLT-1 does not induce xenograft tumor regression.
MB-MDA-231 breast cancer cells were grown as xenografts in
female nude mice for 2 weeks prior to beginning intra-tumoral
injection treatment with either a standard morpholino or
VEGFR1_MOe13 morpholino targeting the human FLT-1
transcript. Change in tumor volume was assessed following a 4
week treatment course. p=0.3
(TIF)
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